A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
Withdrawn · Phase 3 · NCT05316220
Conditions: Ulcerative Colitis (UC)
At a glance
- Research payments reported, 2025
- $4,740
- U.S. investigators named
- 1
- Sites paid
- 1
About the trial
- Sponsor
- AbbVie
- Tested
- Mesalamine (drug), Placebo (drug)
- Dates
- Started 2025-09-15; completion 2026-07-19
- Results posted
- Not yet
Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) characterized by diffuse, continuous inflammation of the colon. This study will assess how safe and effective mesalamine delayed-release capsules are in treating pediatric participants with UC. Adverse events and change in disease activity will be assessed. Delzicol (Mesalamine) is an approved drug being developed for the treatment of Ulcerative Colitis (UC). Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. Around 80 Pediatric participants aged 5 to 17 years with a diagnosis of UC will be enrolled in approximately 45 sites in the United States. Partic…
From ClinicalTrials.gov, last updated 2025-08-12. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $4,740 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.